Table 2.
Training group (n = 14) | Control group (n = 13) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline | 3 months | 18 months | P1 value | P2 value | P3 value | Baseline | 3 months | 18 months | P1 value | P2 value | P3 value | ANOVA 1,2 P value | ANOVA 2,3 P value | ANOVA 1,3 P value | |
Physical performance | |||||||||||||||
CST (repetitions) | 11.5 (± 3.9) | 17.1 (± 4.7) | 17.6 (± 5.8) | 0.00* | 1.0 | 0.00* | 10.5 (± 4.5) | 14.7 (± 5.7) | 15.3 (± 6.3) | 0.00* | 1.0 | 0.01* | 0.3 | 0.9 | 0.4 |
SRH (cm) | 210.4 (± 12.2) | 213.6 (± 13.2) | 210 (± 13.2) | 0.02* | 0.02* | 1.0 | 212.2 (± 14.1) | 211.8 (± 15) | 212.5.8 (± 14.2) | 1.0 | 1.0 | 1.0 | 0.04* | 0.02* | 0.6 |
The IAP pre-activation pattern | |||||||||||||||
Time before prime mover (s) | 0.22 (± 0.42) | − 0.03 (±0.22) | / | 0.04* | / | / | 0.22 (± 0.25) | 0.20 (± 0.18) | / | 0.67 | / | / | 0.08 | / | / |
Subjective self-evaluations | |||||||||||||||
ODI | 40.6 (± 11.9) | 27.4 (± 13.4) | 25.7 (± 15.1) | 0.00* | 1.0 | 0.02* | 41.5 (± 6.1) | 29.5 (± 12) | 27.6 (± 22) | 0.00* | 1.0 | 0.04* | 0.7 | 0.9 | 0.9 |
VAS | 2.7 (± 1) | 2.7 (± 1.3) | 4 (± 2.3) | 1.0 | 0.1 | 0.1 | 3.6 (± 1.5) | 3.2 (± 1.2) | 3.6 (± 2.6) | 1.0 | 0.6 | 1.0 | 0.6 | 0.4 | 0.3 |
Data are reported as mean (SD)
CST, chair stand test, number of stand ups; SHR, standing reach height, numbers represent centimetres; ODI, Oswestry disability index, scoring from 0 to 100, 0 = no pain; VAS, visual analogue scale, scoring from 0 to 10, 0 = “no problems” and 10 = “maximum problems”; Time before prime mover, negative numbers represent time (s) before prime mover, positive represent time (s) after prime mover; P1-value, difference between the baseline’s and 3 months’ mean; P2 value, difference between the 3 months’ and 18 months’ mean; P3 value, difference between the baseline’s and 18 months’ mean; ANOVA, one-way repeated-measure ANOVA; ANOVA 1,2 difference between the baseline’s and 3 months’ mean; ANOVA 2,3 difference between the 3 months’ and 18 months’ mean; ANOVA 1,3 difference between the baseline’s and 18 months’ mean
*Significance difference between the groups, p < 0.05